2. GPCR/G Protein Neuronal Signaling
  3. Somatostatin Receptor
  4. Seglitide

Seglitide  (Synonyms: MK-678; L-363586)

Cat. No.: HY-106103 Purity: 99.30%
COA
SDS
Handling Instructions Technical Support

Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Seglitide

Seglitide Chemical Structure

CAS No. : 81377-02-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of Seglitide:

Seglitide Related Antibodies

Top Publications Citing Use of Products

View All Somatostatin Receptor Isoform Specific Products:

View All Isoforms
SSTR1 SSTR2 SSTR3 SSTR5 SSTR4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus[1][2][3][4].

IC50 & Target[1]

SSTR2

 

In Vivo

Seglitide (50-1000 µg/rat/day; p.o.; daily; up to 49 days) produces a reversible, sustained 11-21% reduction in systolic blood pressure in Streptozotocin (HY-13753)-induced hypertensive diabetic male Sprague-Dawley rats, with no effect on relevant hormones, renin-angiotensin system components, blood glucose, or growth rate[2].
Seglitide (50-100 µg/rat/day; p.o.; daily; 49 days) produces only a transient 11% reduction in systolic blood pressure in male spontaneously hypertensive rats, with no sustained hypotensive effect, and no impact on relevant hormones, renin-angiotensin system components, blood glucose, or growth rate[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, streptozotocin-induced diabetic hypertension)[2]
Dosage: 50 µg/rat/day (days 1-20); 100 µg/rat/day (days 21-49); 1000 µg/rat/day; 100 µg (acute parenteral)
Administration: p.o. (via drinking water, days 1-20); p.o. (via drinking water, days 21-49); p.o. (unspecified duration); parenteral (single acute dose)
Result: Reduced systolic blood pressure of diabetic rats by 14% after 17 days of 50 µg/rat/day treatment (P=0.05).
Maintained systolic blood pressure significantly reduced by 11-21% relative to untreated diabetic rats over days 24-49 with 100 µg/rat/day dose, matching normotensive control levels (98-118 mmHg; repeated measures ANOVA, P<0.003 vs. untreated diabetic rats, P=0.687 vs. normal rats).
Reversed hypotensive effect 5 days after drug withdrawal, with only a 6% reduction in blood pressure (nsd).
Showed no significant effect on plasma renin activity, angiotensin converting enzyme activity, or aldosterone levels in diabetic rats.
Did not alter circulating insulin or glucagon levels in diabetic rats with 1000 µg/rat/day oral dose, but reduced circulating insulin levels by 44% with acute parenteral 100 µg dose (P<0.05).
Had no significant effect on blood glucose levels or growth rate of diabetic rats over 49 days of treatment.
Animal Model: Spontaneously hypertensive (SH) (male)[2]
Dosage: 50 µg/rat/day (days 1-40); 100 µg/rat/day (days 41-49)
Administration: p.o. (via drinking water, days 1-40); p.o. (via drinking water, days 41-49)
Result: Reduced systolic blood pressure of SH rats by 11% at the 10-day time point (P<0.02), with no significant blood pressure reduction observed in subsequent measurements even after dose escalation to 100 µg/rat/day.
Showed no significant effect on plasma renin activity, angiotensin converting enzyme activity, or aldosterone levels in SH rats.
Did not alter blood glucose levels or growth rate of SH rats over 49 days of treatment.
Molecular Weight

808.96

Formula

C44H56N8O7
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Cyclo({Ala(Me)}-Tyr-{d-Trp}-Lys-Val-Phe)
Sequence Shortening

Cyclo({Ala(Me)}-Y-{d-Trp}-KVF)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Seglitide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Seglitide81377-02-8MK-678 L-363586MK678MK 678L363586L 363586L-363586Somatostatin ReceptorSSTRsSSTRspontaneously hypertensive ratsguinea-pig isolated right atriasomatostatin receptor subtype 2GnRH neuronscarbacholN6-cyclohexyladenosinestreptozotocin-diabetic ratsfemale micemale micerat isolated distal colonInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Seglitide
Cat. No.:
HY-106103
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.